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Cavernoma: New insights from an unusual case 
 
Abstract 
Rapid growth in cerebral cavernous malformation is rare. We present the case of a 
71 year old patient with known multiple cavernomas over many years in whom one 
lesion showed rapid expansion in size. Histological examination revealed co-
existence of glioblastoma within the cavernoma. We review the literature for similar 
cases and discuss the potential mechanisms underlying this phenomenon. Review of 
the literature revealed four cases with known cerebral cavernous malformations that 
have later developed, at the same site, a high grade glioma. All reported cases 
involve female patients with age ranging from 25 to 71, with imaging confirming rapid 
growth in the lesion. We conclude that although rare, rapid expansion of existing 
cavernoma should be treated as suspicious for development of other malignant 
tumors, and propose adding the possibility of chronic inflammation in the surrounding 
brain caused by micro-bleeds and hemosiderin deposition from the cavernoma to the 
list of possible causes. 
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Introduction 
Cerebral cavernous malformations (CCMs) are vascular malformations characterized 
by enlarged capillary cavities without intervening brain parenchyma. They are rare, 
with a prevalence of around 0.5% in the general population, accounting for 5-15% of 
all vascular malformations of the central nervous system and can be either sporadic 
or familial(2, 20). Familial cavernomatosis represents 10-15% of the total number of 
cavernoma cases and it is inherited in an autosomal dominant fashion with various 
degrees of penetration(8). Familial cavernomas are multiple with their risk of 
hemorrhage being twice as high compared to sporadic ones(17). Cavernomas are 
usually occult and present with an episode of symptomatic hemorrhage between the 
second and fifth decades of life. Other common presenting symptoms include 
headaches, seizures and focal neurological deficits(20).  
The co-existence of cerebral cavernous malformations and primary brain gliomas is 
rare. It is still unknown why this phenomenon occurs with various unverified theories 
proposed(3, 11, 13, 18, 27). Here we present the case of a 71 year old lady who 
developed glioblastoma multiforme at the site of a pre-existing cavernoma. To our 
knowledge, there have only been five reported cases of malignant gliomas arising at 
the site of pre-existing cavernoma(1, 18, 21, 22, 28). Here, we present our case and 
discuss potential biological pathways for tumor development in patients with CCMs.  
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Case Report  
A 71 year-old woman with a history of multiple cavernomata presented to the 
emergency department with a 3 days history of left sided hemiparesis, facial 
weakness and confusion.  
In the year preceeding this admission she saught the advice of her neurologist 
because of increased seizure frequency and intermittent, profound emotional lability. 
She had been diagnosed with multiple cavernomata in December 2012, after 
developing seizures, which were controlled with levetiracetam and lamotrigine.  
Patient did not receive radiotherapy or radiosurgery for her cavernomata which were 
managed conservatively with imaging surveillance under the care of the 
neurovascular MDT (figures 1,2). She underwent formal genetic testing which 
identified a heterozygous single nucleotide substitution in the CCM2 gene. 
On this admission, patient had left sided hemiparesis (MRC grade 4/5), facial 
weakness, difficulty following commands, as well as difficulty with number 
comprehension, calculation, and reading. MRI revealed a heterogeneously 
enhancing lesion with T1 shortening and peripheral contrast enhancement consistent 
with a high grade tumor (figure 3).  
The patient underwent craniotomy and resection with histopathological examination 
revealing glioblastoma multiforme, WHO grade IV, IDH1 negative and cavernoma 
(figure 4). In the tumor sample the MGMT promoter gene was unmethylated. She 
was subsequently treated with radiation and chemotherapy as per Stupp protocol for 
the treatment of glioblastoma.  
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Discussion  
Though rare (Table1), the co-existence of high grade gliomas and cavernomas is 
recognized, but their presence in combination might be more frequent than reported. 
Various theories have been proposed attempting to describe the etiological 
relationship between the two, including (a) fortuitous association (b) sequential – 
secondary due to reactive or neoplastic glial change to a previously existing vascular 
malformation or vice versa under the influence of tumor angiogenic factor (c) genetic 
predisposition (d) common viral origin (e) radiation exposure(3, 11, 13, 18, 27). 
The common viral origin theory has been proposed more than three decades ago but 
the supporting evidence is insufficient. Polyoma virus, which belongs to papovavirus 
family, is a pathogen only for mice and is known to have dose dependent 
tumorigenic effect. High doses can cause multiple capillary, cystic, or cavernous 
hemangiomas in brain and spinal cord with the formation of the latter greatly 
enhanced by suppression of the immune system(11, 25). Polyoma virus is not known 
to induce glial tumors but it has been shown that another papovavirus, SV 40 virus, 
causes ependymomas in new-born hamsters(9, 16). Although of interest, 
applicability of this knowledge to humans remain questionable.  
We have recently gained significant knowledge surrounding the molecular genetics 
of cavernomas through the study of hereditary cavernoma syndromes that confirm 
link of the latter to three genes: CCM1, CCM2, CCM3(6). A loss-of-function mutation 
to any of these genes produces an autosomal dominant syndrome that is 
characterized by one or more cavernomas. Cavernomas can also develop following 
somatic mutations of these genes(26). Interestingly, monosomy of chromosome 7 
that hosts both CCM1 and CCM2, is common following hyper-activation of Ras 
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oncogenes or mutation of the neurofibromatosis-1 protein indicating that genetic 
factors within glial and Schwann cell tumors may lead to subsequent development of 
cavernomas(18). 
Additionally, growth factors and cytokines expressed by vascular anomalies in the 
brain have been shown to promote tumorigenesis. Dai et al, investigated the role of 
platelet-derived growth factor and platelet-derived platelet factor receptor (PDGF and 
PDGFR) in cell cultures and in vivo in mice. They presented evidence that some low-
grade gliomas may be comprised of proliferating glial progenitor cells with blocked 
ability to differentiate whereas malignant gliomas have acquired mutations that 
disrupt the cell cycle arrest pathways such as by loss of Ink4a-Arf. Co-expression of 
PDGF and PDGFR has been demonstrated in human gliomas indicating that 
autocrine stimulation may be involved in the formation of malignant gliomas. By 
introducing PDGF to neural progenitors and astrocytes they showed gliomagenesis 
with Ink4a-Arf loss promoting malignant phenotype(7). Various other factors that are 
secreted by gliomas or the cells surrounding them as well as vascular malformations, 
including vascular endothelial growth factor (VEGF) and angioprotein-1 have been 
shown to promote the development of cavernous malformations but also the 
progression of various intracranial tumors(10, 14, 23, 24).  
Another possible explanation for malignant changes in glial cells adjacent to 
cavernomas may be chronic inflammation caused by micro-bleeds and hemosiderin 
deposition from the cavernoma. Chronic inflammation is known to promote 
malignancy in a range of tissues such as colorectal carcinoma in Chron’s disease, 
bladder cancer with the use of indwelling catheters and gastric adenocarcinoma with 
H. Pylori infection(5). It is therefore possible that similar processes over time may 
also lead to malignant transformation of glial cells in proximity of the cavernomas.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The fact that all cases described had a long history of prior cavernoma is consistent 
with such a hypothesis of chronic irritation deriving the process of tumor formation. 
Additionally, in three out of these five cases evidence of previous hemorrhages is 
reported in the form of hemosiderin deposits that were identified either 
intraoperatively(28) or following histopathological examination of the specimens(1, 
22).  
Not surprisingly, in all cases there was significant change in the size of the 
malformation at the time of the diagnosis of high grade gliomas, as well as new or 
worsening of pre-existing seizure activity with the exception of the posterior fossa 
case, but little is still known about the change in size of cavernomas over time. First 
to describe dynamic changes of these malformations was Pozzati in 1989, 
presenting three cases in which the cavernomas grew substantially over time(19). 
Similarly, rapid growth with aggressive behavior despite multiple surgical excisions in 
a tumor with histologic confirmation of cavernoma has been described by Stacey in 
2000(12). In contradiction, Kim in 1997 showed decrease in the size over time and 
more specifically from an average diameter of 14.2mm to 9.1mm with repeat 
imaging(15). The biggest study demonstrating dynamic changes in the size of 
cavernomas by Clatterbuck published in 2000, did not favor either growth or 
shrinking over time. In this study, 68 patients with 114 cavernomas underwent serial 
imaging over a period of 3.7 years. 22% of the lesions were stable in size over time, 
43% increased in size and 35% decreased. Interestingly, many of the above 
reported cavernomas had both periods of increase and decrease in size(4).    
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CONCLUSION 
It is unusual for cavernomas to grow rapidly. We report a case with rapid expansion 
of a known cavernoma with histology confirming glioblastoma embedded within the 
malformation, radically altering the management strategy.  The biological mechanism 
is still speculative but may be related to common genetic pathways for both lesions 
or tumorigenic cytokines and growth factors released by vascular malformations. We 
propose adding the possibility of chronic inflammation in the surrounding brain 
caused by micro-bleeds and hemosiderin deposition from the cavernoma to this list.  
From a practical point, in rapidly growing cavernomas, a low threshold to obtain 
histological confirmation, either in the form of biopsy or resection, should be 
employed to rule out malignancy.   
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Cavernoma: New insights from an unusual case 
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Table 1 Literature review identified five cases with malignant gliomas developing at the same site with known cavernoma. GBM: glioblastoma, CCM: 
cerebral cavernous malformation. RF: right frontal, LT: left temporal, LP: left parietal, V: vermis 
 Gend
er 
Age Background Presentation Site Diagnosis Histopathology 
 
Case 1
22 
 
F 
 
71 
 
Fit and well 
 
Seizures 
 
RF 
 
Cavernoma 
 
Anaplastic 
astrocytoma 
 
Case 2
18 
 
F 
 
69 
Fit and well 
Family history of 
mCCM 
 
Dysphasia, seizures 
 
LT 
Multiple 
cavernomas 
 
GBM 
 
Case 3
28 
 
F 
 
60 
 
Known mCCM 
 
Left sided hemiparesis, 
1xseizure 
 
RF 
Multiple 
cavernomas 
 
GBM 
 
 
Case 4
1 
 
F 
 
25 
 
 
Fit and well 
Partial seizures, 
hemiparesis 
 
LP 
 
Cavernoma 
Anaplastic 
astrocytoma 
 
Case 5
21 
 
F 
 
54 
 
unknown 
Headache, nausea, 
vomiting 
 
 
V 
 
Cavernoma 
Anaplastic 
oligodendroglioma 
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Figure 1. Initial MRI in January 2013 showing multiple intracranial lesions with T1 shortening 
consistent with multiple cavernomas with evidence of previous hemorrhage 
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Figure 2. Interval MRI in June 2013 showing no significant changes in appearances compared to the 
initial MRI. 
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Figure 3. Imaging in April 2015 when patient presented with increasing seizure activity and 
hemiparesis showing significant increase in the size of the lesion with heterogeneous enhancement 
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Figure 4 showing a largely necrotic pleomorphic tumor diffusely infiltrating the grey and white matter, small pieces of 
hippocampus and many abnormally formed blood vessels. The tumor is composed of large cells with pleomorphic oval-
shaped nuclei and prominent nucleoli arranged in solid bundles within a fibrillary background. Large areas of 
pseudopalisading necrosis, endothelial cell proliferation with glomeruloid structure formation and brisk mitotic activity is 
noted. There are areas with collection of hyalinised and dilated blood vessels with different caliber and wall thickness; 
some with thrombosis and calcification. EVG confirms the vascular malformation consistent with cavernoma 
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1 
 
Cavernoma: New insights from an unusual case 
 
 
 
 
Highlights 
 
• Five reported cases with co-existence / development of high grade 
gliomas in patients with long history of cavernomas 
• Rapid growth in a cavernoma should raise suspicion of malignancy 
• Theories proposed cannot explain co-existence of two lesions 
• We propose adding chronic inflammation due to micro-bleeds as 
causative mechanism 
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